Blum Holdings, Inc. Doubles Revenue Potential with Execution of Amended and Restated LOI, Accelerating Acquisition of Premier Northern California Dispensary - Blum Holdings (OTC:BLMH)

Schneider Electric plans to acquire PTC for $22.6B, its largest deal ever. CEO Olivier Blum cites digital transformation and AI as key drivers, aiming to bridge physical and digital worlds. The acquisition follows Schneider's July bid for Cognite, focusing on industrial AI and data contextualization. Financing includes $6B in equity and $17B in debt. PTC's portfolio is seen as a strategic fit for Schneider's goals.

Aeroméxico's credit rating was upgraded to 'BB-' from 'B+' by S&P Global Ratings, citing its resilient business model, profitability, and ability to manage costs amid industry volatility. The ratings on its 2029 and 2031 notes were also raised. Aeroméxico's premium service, strategic capacity management, and geographic diversification support its financial strength.

Eli Lilly's shares rose 1.21% to $1,297.37 after its experimental drug retatrutide showed superior weight loss and blood sugar control in a head-to-head trial with Ozempic. The 80-week trial in type 2 diabetes patients showed retatrutide patients lost 47.4 pounds on average, compared to 20.9 pounds with Ozempic. However, more retatrutide patients discontinued treatment due to adverse events. Lilly's market value is $1.22 trillion with a P/E ratio of 44.08, indicating high investor expectations.

IREN Limited (IREN) stock dropped 35% in a month due to concerns about high borrowing costs. Analyst Mike Colonnese reaffirmed a Buy rating with a $74 price target, citing industry growth and IREN's expansion in Europe. AI cloud industry contract values doubled to $68.4 billion in Q3, with higher pricing. IREN plans a 300MW campus in Spain and has a deal with Microsoft.

Genmab (GMAB) stock rose nearly 30% to an all-time high after positive Phase 3 trial results for its experimental head and neck cancer treatment, Petosemtamab, combined with Merck's Keytruda. The trial met primary goals, showing a 50% reduction in death risk and tripled tumor response odds. The company also reported positive Phase 3 results for its ovarian cancer drug, Rina-S, last week. Retail sentiment on Stocktwits turned bullish.

UBS reduced its price target for Under Armour (NYSE:UA) by 11% to $8, citing bearish sentiment, declining US website traffic, and slower growth in China. Despite this, UBS expects Q2 2027 earnings to meet forecasts and maintains a full-year EPS outlook of $0.08 to $0.12. The stock has fallen 35.5% in three months.